Tag Archives: Eisai’s

Data favor Merck, Eisai’s Keytruda-Lenvima as the winner in kidney cancer, but window still open for Bristol Myers: analyst

The immuno-oncology data showdown between team Merck and team Bristol Myers Squibb in kidney cancer appears to have a winner in the eyes of at least one analyst. But that doesn’t mean the other party has lost the fight. After last week’s American Society of Clinical Oncology’s Genitourinary Cancers Symposium, Merck and Eisai’s Keytruda-Lenvima combo is the “clear… Read More »